Kevin Friedman

Chief Executive Officer at Kelonia Therapeutics, Inc.

Health Technology

Profile

Kevin Friedman is the founder of Kelonia Therapeutics, Inc. He currently holds the titles of President, Chief Executive Officer, and Director at the company.

Kevin Friedman active positions

Companies	Position	Start
Kelonia Therapeutics, Inc. Kelonia Therapeutics, Inc. BiotechnologyHealth Technology Kelonia Therapeutics, Inc. is a company based in Cambridge, MA that is pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS™). The company's simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. Initially focused on developing transformational in vivo CAR T therapies for hematologic cancers, Kelonia Therapeutics is building a pipeline of genetic medicines for a range of diseases, with the bold goal of making genetic medicines accessible to every patient in need, when and where they need them. The company was founded by Michael Fischbach, Michael Birnbaum.	Chief Executive Officer	-

All active positions of Kevin Friedman

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Kevin Friedman's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Kelonia Therapeutics, Inc. Kelonia Therapeutics, Inc. BiotechnologyHealth Technology Kelonia Therapeutics, Inc. is a company based in Cambridge, MA that is pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS™). The company's simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. Initially focused on developing transformational in vivo CAR T therapies for hematologic cancers, Kelonia Therapeutics is building a pipeline of genetic medicines for a range of diseases, with the bold goal of making genetic medicines accessible to every patient in need, when and where they need them. The company was founded by Michael Fischbach, Michael Birnbaum.	Health Technology